This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dutcher, J. P. Search for Related Content PubMed PubMed Citation Articles by Dutcher, J. P.

Mammalian Target of Rapamycin Inhibition

Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that has been increasingly recognized as key to the regulation of cell growth and proliferation. mTOR either directly or indirectly regulates translation initiation, actin organization, tRNA synthesis, ribosome biogenesis, and many other key cell maintenance functions, including protein degradation and transcription functions. Inhibition of mTOR blocks traverse of the cell cycle from the G₁ to S phase. Preclinical data show inhibition of tumor growth in a number of cell lines and xenograft models. Clinical trials are ongoing. In metastatic renal cell cancer, both tumor regression and prolonged stabilization have been noted. mTOR inhibition appears to be a key pathway that may be useful in antitumor therapy. Renal cell cancer may be particularly susceptible through both the translation inhibition pathway and pathways that enhance HIF-1 gene expression, a factor believed to stimulate growth in metastatic renal cell cancer. Additional clinical trials that use agents that inhibit mTOR are ongoing.

This article has been cited by other articles:

				S. Romano, M. Mallardo, F. Chiurazzi, R. Bisogni, A. D'Angelillo, R. Liuzzi, G. Compare, and M. F. Romano The effect of FK506 on transforming growth factor {beta} signaling and apoptosis in chronic lymphocytic leukemia B cells Haematologica, July 1, 2008; 93(7): 1039 - 1048. [Abstract] [Full Text] [PDF]

				R. M. Bukowski How I Treat Renal Cell Carcinoma J. Oncol. Pract, May 1, 2008; 4(3): 150 - 152. [Full Text] [PDF]

				K. Gendron, J. Charbonneau, D. Dulude, N. Heveker, G. Ferbeyre, and L. Brakier-Gingras The presence of the TAR RNA structure alters the programmed -1 ribosomal frameshift efficiency of the human immunodeficiency virus type 1 (HIV-1) by modifying the rate of translation initiation Nucleic Acids Res., January 17, 2008; 36(1): 30 - 40. [Abstract] [Full Text] [PDF]

				A. M. Ramos, C. Fernandez, D. Amran, P. Sancho, E. de Blas, and P. Aller Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells Blood, May 15, 2005; 105(10): 4013 - 4020. [Abstract] [Full Text] [PDF]